Turning insights into calls to action for MM patient care
The Unite for MM initiative was developed by a steering committee that included representatives from across the multiple myeloma (MM) community, and surveyed over 2000 patients and health care professionals (HCPs) about their challenges with relapsed/refractory multiple myeloma (RRMM)1
- Patients and HCPs have different priorities when it comes to RRMM treatments, and these treatments can place a heavy toll on patients
- Many patients, including those of ethnicities/races other than White,a also lack awareness of approved immunotherapies, or have not been offered these treatments
aRacial data available only for patients in the US. Ethnicities/races other than White included Asian or Pacific Islander, Black or African American, Hispanic or Latino, Native American or other indigenous community, or other.1
Key Findings and Actions to Consider Developed in Partnership With the Steering Committee
Different HCP-Patient Treatment Decision-Making Priorities1
Call to Action
Collaborate to Relieve Treatment-Related Burdens and Identify Patient Treatment Goals
Differing Opinions on the Most Challenging Side Effects1
Call to Action
Reduce Treatment Burdens by Using a Comprehensive Approach to Manage Side Effects
Low Patient Awareness of and Confidence in BsAbs and CAR T-Cell Therapies1
BsAb, bispecific antibody; CAR, chimeric antigen receptor.
Practical and Educational/Experience Challenges to Immunotherapy Use1
Access the survey publication to deepen your understanding of key insights
By encouraging conversations between patients and HCPs, increasing education, decreasing logistic burdens, gathering data, and strengthening links between members of the MM community, Pfizer hopes to optimize care and improve patient outcomes.
Pfizer thanks the Steering Committee, as well as the HCPs and patients who responded to the surveys and helped collect these valuable data.
Reference
- Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence.
2025;19:1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com